Clinical trial
Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
NCT00245921 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00245921 |
|---|---|
| Title | Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception |
| Official title | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg in a Continuous Daily Regimen for Oral Contraception |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Contraception |
| Intervention type | Drug |
| Interventions | Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg |
| Enrollment | 2,000 |
| Start date | Feb 1, 2003 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Oct 28, 2005 |
| Last update posted | Feb 8, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: